Indapamide
Sponsors
Centre Hospitalier Regional Universitaire De Tours, Region Midtjylland, LaborMed Pharma S.A., West China Hospital, Peking University Third Hospital
Conditions
High-normal Blood PressureHypertensionHypoparathyroidismMultiple SclerosisRenal InsufficiencyType 2 Diabetes MellitusUncontrolled Hypertension IN patients with moderate to severe chronic Kidney disease
Phase 2
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
CompletedNCT05103332
Start: 2021-11-05End: 2024-09-13Updated: 2025-11-03
Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)
Not yet recruitingNCT07765212
Start: 2026-09-01End: 2028-09-01Target: 75Updated: 2026-08-14
Phase 3
Phase 4
A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM
CompletedNCT00980187
Start: 2008-03-31End: 2010-08-31Updated: 2011-06-15
Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency
CompletedNCT01172431
Start: 2010-09-30End: 2013-12-31Updated: 2014-06-24
The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure
NCT04455178
Start: 2020-09-23End: 2023-12-31Target: 200Updated: 2021-12-08
Treatment with Indapamide in Patients with Post-Surgical Hypoparathyroidism
RecruitingCTIS2024-516000-41-01
Start: 2025-06-04Target: 24Updated: 2025-02-26
Unknown Phase
Spironolactone Versus Indapamide in Obese and Hypertensive Patients
NCT03626506
Start: 2019-02-13End: 2020-12-31Target: 400Updated: 2019-12-03
Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population
CompletedNCT07652567
Start: 2007-01-01End: 2026-04-30Updated: 2026-06-17